

Date of preparation: 18 April 2024

Issuer's abbreviated name: SYNEKTIK SA

Current report: 23/2024 ESPI

Subject: Information on the conclusion of a significant agreement on the sale of a robotic system

Legal basis: Article 17 Section 1 of MAR – confidential information

Body of the report:

Time of publication: 11:51 a.m.

The Management Board of Synektik SA (hereinafter: Company) reports that significant agreements have been concluded with Samodzielny Publiczny Szpital Kliniczny im. prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego [Professor W. Orłowski Independent Public Clinical Hospital, Post-graduate Medical Education Center] with its registered office in Warsaw, ul. Czerniakowska 231, 00-416 Warsaw (hereinafter: Hospital) and the consortium established by Synektik SA as consortium leader and BNP Paribas Lease Group Sp. z o.o. with its registered office in Warsaw, ul. Grzybowska 78, 00-844 Warsaw as consortium member (hereinafter: Consortium).

This agreement pertains to the installment sale, supply, assembly, installation and commissioning of the da Vinci robotic surgery system for the Hospital along with accompanying equipment, additional surgical training console, staff training and warranty maintenance care as well as successive deliveries of instruments and accessories to the da Vinci robotic system for a period of 24 months. These agreements were concluded as a result of the public tender proceeding conducted in the form of an unlimited tender for the maximum net amount of PLN 15,028,752.45.

The da Vinci system delivery will take place within a term of up to 2 weeks from the date of concluding the agreement. The warranty period for delivery of the robotic system is 24 months from signing the final acceptance report. The other clauses in the agreements concluded by the Consortium do not deviate from the standards generally used in contracts of this type.

The signing of these agreements has been deemed to be significant by the Management Board of Synektik SA since their combined maximum net value exceeds 5% of the equity of the Synektik Group disclosed in the last periodic report, meaning that it surpasses the level prescribed internally in the Company in its individual reporting standards. The proceeds generated by executing the delivery of the robotic system will affect the sales results in the 2023 financial year lasting from 1 October 2023 to 30 September 2024.

Persons representing the Issuer:

Cezary Kozanecki – President of the
Management Board